Comment by surgical_fire
7 hours ago
Or they bleed money like crazy, and their margins are pretty awful. Which is the correct answer.
Your $200 subscription is a major net loss for them. The vast majority that pays for that would cancel in a heartbeat the moment they had to pay API prices. Which may or may not be profitable, I am not entirely sure. But for the sake of argument, let's assume that it is.
Are we still calculated $200 subscription token spend based on their highly inflated API token cost and then concluding that they must be losing money on all $200 subscriptions?
Are their API token costs highly inflated? I see no evidence of that.
Why are we using consumer prices when the vast majority of their revenue is from enterprise api usage?
Wihout insight on how much enterprise is paying, it is impossible to draw any conclusions. Unless you have any access to their contracts and are willing to share evidence? I find that highly unlikely.
People here throw around crazy numbers - the dude above was claiming they have some insane good margins, numberd that he took out of his ass.
The only evidence I have is that they are incredibly unprofitable, and they keep raising insane amounts of capital like crazy.
There was a leak sometime ago that they were EBITDA positive during a quarter where they didn't pay for part of their compute. And EBITDA is a cute metric to use when depreciation is actually very important to them, as a model from a year or so ago is nearly worthless.
serving models is very profitable (70%+) but the issue is you need to invest in training the next iteration. but so far all of anthropics models have been profitable fully loaded
the vast majority of the labs revenue is from enterprise api usage (theres public sources from the information and ramp). but the risk there is customer concentration, where most of the revenue comes from other tech companies and a chunk of it is from foreign labs distilling
so i am drawing a conclusion that the labs' business model is good, maybe not as great as boosters think it is. if they make real progress on the biosciences like drug discovery that could turn it into an amazing business
1 reply →